Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | Evaluating new CAR constructs for chronic hepatitis B and HBV-associated HCC in the clinic

Ulrike Protzer, MD, Technical University of Munich, Munich, Germany, shares her excitement towards their chimeric antigen receptor (CAR) constructs being investigated as a novel clinical approach to treat chronic hepatitis B and hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.


Share holder and board member of SCG Cell Therapy.
Ad hoc scientific advisor for AbbVie, Arbutus, Gilead, GSK, Johnson & Johnson, Roche, Sanofi, Sobi, and Vaccitech.